

# Peng Yue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11050796/publications.pdf>

Version: 2024-02-01

15  
papers

3,679  
citations

567281

15  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

7270  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diverse somatic mutation patterns and pathway alterations in human cancers. <i>Nature</i> , 2010, 466, 869-873.	27.8	1,189
2	Loss of Protein Structure Stability as a Major Causative Factor in Monogenic Disease. <i>Journal of Molecular Biology</i> , 2005, 353, 459-473.	4.2	438
3	SNPs3D: candidate gene and SNP selection for association studies. <i>BMC Bioinformatics</i> , 2006, 7, 166.	2.6	383
4	Somatic Mutations in p85 $\beta$ Promote Tumorigenesis through Class IA PI3K Activation. <i>Cancer Cell</i> , 2009, 16, 463-474.	16.8	291
5	TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer. <i>Science Signaling</i> , 2011, 4, ra41.	3.6	252
6	Identification and Analysis of Deleterious Human SNPs. <i>Journal of Molecular Biology</i> , 2006, 356, 1263-1274.	4.2	237
7	Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1132-1144.	4.1	231
8	Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. <i>Blood</i> , 2009, 114, 2721-2729.	1.4	205
9	miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to-Mesenchymal Transition in Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e66502.	2.5	111
10	Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1026-1035.	4.1	94
11	Navitoclax Enhances the Efficacy of Taxanes in Non-Small Cell Lung Cancer Models. <i>Clinical Cancer Research</i> , 2011, 17, 1394-1404.	7.0	80
12	Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 853-864.	4.1	67
13	Inferring the functional effects of mutation through clusters of mutations in homologous proteins. <i>Human Mutation</i> , 2010, 31, 264-271.	2.5	48
14	CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma. <i>Science Translational Medicine</i> , 2011, 3, 74ra22.	12.4	34
15	Analytical methods for inferring functional effects of single base pair substitutions in human cancers. <i>Human Genetics</i> , 2009, 126, 481-498.	3.8	19